SuperworthWest Pharmaceutical Services, Inc. WST
Medical - Instruments & Supplies, Healthcare
$366.48
−1.65%
- Market cap
- $25.8B
- PE
- 46.9×
- 10y median 45.8×
- Forward PE
- Price to sales
- 7.8×
- EV/EBIT
- 36.9×
- Revenue, 12 months
- $3.3B
- +12% on a year ago
- Net margin
- 17.0%
- Free cash flow yield
- 1.7%
West Pharmaceutical Services trades at 46.9× trailing earnings, near its ten-year median. Revenue was $3.3B over the last twelve months, up 12% on a year earlier with a 17% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $732M | $695.4M | $702.1M | $746.9M | $748.8M+2% | $698M+0% | $766.5M+9% | $804.6M+8% | $805M+8% | $844.9M+21% | $872.3M+14% | |
| Cost of revenue | $453.8M | $465.2M | $472.1M | $482.2M | $475.2M+5% | $466.1M+0% | $492.6M+4% | $510.3M+6% | $501.1M+6% | $548.5M+18% | $543.1M+10% |
| Gross profit | $278.2M | $230.2M | $230M | $264.7M | $273.6M−2% | $231.9M+1% | $273.9M+19% | $294.3M+11% | $303.9M+11% | $296.4M+28% | $329.2M+20% |
| R&D | $18.4M | $17.6M | $17.5M | $15.5M | $18.5M+1% | $16.3M−7% | $19.1M+9% | $17.1M+10% | $21.8M+18% | $15.8M−3% | $19.7M+3% |
| SG&A | $90M | $86.7M | $83M | $83.5M | $85.3M−5% | $88M+2% | $95.9M+16% | $102.7M+23% | $107M+25% | $99.5M+13% | $117.6M+23% |
| $160.9M | $122.8M | $126.2M | $161.3M | $159.6M−1% | $107M−13% | $153.7M+22% | $167.6M+4% | $156.6M−2% | $177.1M+66% | $179.1M+17% | |
| Interest expense | $1.1M | $1.5M | $1.5M | $700K | $0 | $400K−73% | $100K−93% | $100K−86% | $0 | $0 | $0 |
| Pre-tax income | $168.2M | $127.4M | $128.7M | $164.5M | $164.9M−2% | $110.5M−13% | $157M+22% | $171.9M+5% | $161.5M−2% | $180.1M+63% | $180.1M+15% |
| $34.5M | $16.4M | $21.9M | $32.4M | $36.8M+7% | $24.1M+47% | $30.2M+38% | $34M+5% | $33.3M−10% | $44.7M+86% | $32.2M+7% | |
| Net income | $137M | $115.3M | $111.3M | $136M | $130.1M−5% | $89.8M−22% | $131.8M+18% | $140M+3% | $132.1M+2% | $138.8M+55% | $154M+17% |
| $1.83 | $1.55 | $1.51 | $1.85 | $1.78−3% | $1.23−21% | $1.82+21% | $1.92+4% | $1.82+2% | $1.92+56% | $2.15+18% | |
| 75M | 74.3M | 73.7M | 73.4M | 73.7M−2% | 73M−2% | 72.5M−2% | 72.6M−1% | 72.7M−1% | 72.4M−1% | 71.3M−2% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Instruments & Supplies within ten times West Pharmaceutical Services's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| WSTWest Pharmaceutical Services, Inc. | $25.8B | 46.9× | 45.8× | 7.8× | +12% | 17.0% | |
| RMDResMed Inc. | $32.6B | 21.7× | 37.3× | 5.8× | +10% | 26.9% | |
| MDLNMedline Inc. | $46.6B | 41.2× | 32.3× | 1.6× | +15% | — | |
| BDXBecton, Dickinson and Company | $49.1B | 54.3× | 47.3× | 2.4× | −3% | 4.5% | |
| ISRGIntuitive Surgical, Inc. | $146.4B | 47.5× | 69.0× | 13.3× | +21% | 28.4% | |
| Peer median | $47.8B | 44.4× | 42.3× | 4.1× | +12% | 26.9% |
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .